The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma.
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Mersana; Regeneron; Tesaro
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Regeneron (Inst); Surface Oncology (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
(OPTIONAL) Uncompensated Relationships - Merck
 
Nicoletta Colombo
Honoraria - Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; mersana; MSD Oncology; Novartis; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Ana Oaknin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Immunogen; Mersana; PharmaMar; Roche; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Clovis Oncology (Inst); Eisai (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Lydia Gaba
Honoraria - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; MSD Oncology
Consulting or Advisory Role - AstraZeneca Spain; GlaxoSmithKline; MSD Oncology
 
Jean-Sebastien Frenel
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Lilly; Novartis; Novocure; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; Novartis; Pfizer; Roche
 
Nicole Nevadunsky
Honoraria - Blueprint Medicines
Consulting or Advisory Role - LEK; LEK
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst); Tesaro (Inst)
 
Victoria de Giorgio-Miller
Employment - AstraZeneca
 
Pingping Ni
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline
 
Dana C. Ghiorghiu
Employment - AstraZeneca; AstraZeneca (I)
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I)